All Posts Tagged With: "Artemisinin"

Dr. Gordon comments on cardiovascular disease & other topics

Blood clots kill and they make today’s focus on cholesterol looks badly misguided. Many natural approaches help and add Carnitine to that list. I recently attended the Nevada Homeopathic and Integrative Medicine conference in Reno.

David Berg is an expert private consultant on blood coagulation issues. His presentation there was videotaped will be available to purchase from the association (President in Nevada is Dr Michael Gerber). David Berg made it clear that his own prostate cancer went away using heparin based therapy. He agrees with me that Coumadin is never the correct answer. He is very impressed, however, with the benefits he sees with testing by reference labs he refers his clients to and with treatment with natural products particularly Boluoke (Lumbrokinase). 

I reminded the attendees that EDTA MAKES HEPARIN WORK BY MOUTH, documented in 1960, published in Nature and immediately patented by Riker. I have used this to eliminate fatal heart attacks in all my patients for well over 20 years now.  It is the basis for the product Beyond Chelation Improved, as this took advantage of the $10 million in research by Dr Lester Morrison, who found a HEPARIN-LIKE action from a particular seaweed based ingredient. When I added ORAL EDTA to his institute formula, we immediately had a safe oral anticoagulant and I use this as my alternative to Coumadin or Heparin when I incorporate the essential fatty acids OMEGA 3 and PRIMROSE OIL to the garlic, ginkgo and EDTA based formula.

Of course David Berg injected Lovenex for his cancer and others might use other forms of Heparin by injection. But, the idea that fibrin is an issue in delivering local oxygen to tissues where according to the Warburg research, anaerobic metabolism supports cancer, we might expect that anything that enhances local oxygen levels in tissues could be beneficial then for any cancer.  My experience in chelation and thermography has made me very aware of the need to optimize tissue oxygen levels and the ability of chelation to help that occur.

The attached article suggests that one more nutrient Carnitine may be of further use in lowering fibrinogen and even C-reactive protein levels. We know that inflammation sets the stage for hypercoagulability so this is another useful nutrient to add to my long list of documented nutrients that are useful in cancer like Vitamin C, Curcumin, Artemisinin, Quercetin alone or as found with pancreatic enzymes in Wobenzym.

Garry F. Gordon MD,DO,MD(H)
President, Gordon Research Institute
www.gordonresearch.com

Link: http://www.nhiondemand.com/HSJArticle.aspx?id=912&utm_source=NHI+OnDemand+Newsletter+List&utm_campaign=a61eed16f7-HSJ_Sep30_2010&utm_medium=email

Excerpt:

NHIondemand.com
Date: 9/27/2010

L-Carnitine Plays a Role in Preventing Cardiovascular Disease.

Cardiovascular disease or heart disease is a class of diseases that involve the heart or blood vessels (arteries and veins). There are several risk factors for cardiovascular disease that are essentially immutable. These are older age, male gender, and a family history of CVD. Additionally, three major risk factors identified include cigarette smoking, dyslipidemia (high cholesterol), and hypertension. Other identified factors associated with increased risk for cardiovascular disease include physical inactivity, sleep problems, diabetes mellitus, rheumatoid arthritis, obesity, excessive intake of alcohol, thrombotic and fibrinolytic factors, elevated homocysteine levels, certain infections and inflammation, exogenously administered estrogens and androgens, certain psychosocial factors, increased fasting glucose. and frequency of migraines. The synergism of the presence of multiple risk factors must also be considered.

L-carnitine is an amino acid that is synthesized from the amino acids lysine and methionine. Because it can be synthesized in the body, L-carnitine is usually not considered to be an essential nutrient. However, it could be classified as an essential nutrient for premature infants and other individuals who are not able to synthesize it in sufficient amounts. In addition to its use in clinical conditions, L-carnitine is used with exercise programs to reduce muscle soreness.

A study published in the journal Renal Failure investigated the effects of L-carnitine on plasma coagulation and anticoagulation. The researchers enrolled thirty-six hemodialysis patients and the patients randomly received either 1000 mg a day L-carnitine or a placebo for 12 weeks. Blood was collected at the beginning of the trial and at the end to compare changes in plasma activity. The results were the L-carnitine group experienced significant reductions in serum C-reactive protein (marker for systemic inflammation) and plasma fibrinogen (an inflammation-related coagulator) in comparison to the placebo group. The authors stated “Therefore, l-carnitine may play an effective role in preventing cardiovascular diseases in these patients.”1

1 Hakeshzadeh F, Tabibi H, Ahmadinejad M, et al. Effects of L-Carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients. Ren Fail. 2010;32(9):1109-14.

Antiviral Activities of Artemisinin, Artesunate

Traditional Chinese medicine commands a unique position among all traditional medicines because of its 5000 years of history. Our own interest in natural products from traditional Chinese medicine was triggered in the 1990s, by artemisinin‐type sesquiterpene lactones from Artemisia annua L. As demonstrated in recent years, this class of compounds has activity against malaria, cancer cells, and schistosomiasis. Interestingly, the bioactivity of artemisinin and its semisynthetic derivative artesunate is even broader and includes the inhibition of certain viruses, such as human cytomegalovirus and other members of the Herpesviridae family (e.g., herpes simplex virus type 1 and Epstein‐Barr virus), hepatitis B virus, hepatitis C virus, and bovine viral diarrhea virus. Analysis of the complete profile of the pharmacological activities and molecular modes of action of artemisinin and artesunate and their performance in clinical trials will further elucidate the full antimicrobial potential of these versatile pharmacological tools from nature. Continued

Malaria Vaccine study

Impact of RTS,S/AS02A and RTS,S/AS01B on Genotypes of P. falciparum in Adults Participating in a Malaria Vaccine

Clinical Trial

RTS,S, a candidate vaccine for malaria, is a recombinant protein expressed in yeast containing part of the circumsporozoite protein (CSP) sequence of 3D7 strain of Plasmodium falciparum linked to the hepatitis B surface antigen in a hybrid protein. The RTS,S antigen is formulated with GSK Biologicals’ proprietary Adjuvant Systems AS02A or AS01B. A recent trial of the RTS,S/AS02A and RTS,S/AS01B vaccines evaluated safety, immunogenicity and impact on the development of parasitemia of the two formulations. Parasite isolates from this study were used to determine the molecular impact of RTS,S/AS02A and RTS,S/AS01B on the multiplicity of infection (MOI) and the csp allelic characteristics of subsequent parasitemias. Continued

Artemisinin-Resistant Malaria Detected in Western Cambodia

NEW YORK (Reuters Health) Jul 29 – New research indicates that artemisinin resistance among Plasmodium falciparum isolates is common in western Cambodia and that in vitro testing may give false results.

Findings from another study indicate that inoculation of intact sporozoites can induce protection against malaria challenge. Both studies are reported in The New England Journal of Medicine for July 30. Continued